Authors: Gianluca Marucci Luca Morandi
Publish Date: 2011/05/31
Volume: 105, Issue: 2, Pages: 397-400
Abstract
Although pleomorphic xanthoastrocytoma PXA is currently designed as a grade II glioma according to the WHO classification a significant percentage of the tumors undergo malignant progression In this study the MGMT methylation status was examined in 11 PXA patients to determine if a biologic rationale exists to support the use of temozolomide TMZ for treatment of aggressive PXA There were 9 cases of PXA grade II and 2 cases of PXA with anaplastic features In the MGMT methylation study only 2 181 of the 11 tumor samples tested by MSqLNAPCR were positive for MGMT promoter methylation In contrast other cases including PXAs with anaplastic features were unmethylated In addition a tumor recurrence was found to be unmethylated Thus MGMT promoter methylation is not frequent in PXA and our results raise doubts about the benefits of treating indistinctly aggressive PXA with TMZ
Keywords: